Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Short report

Stability studies of HIV-1 Pr55gagvirus-like particles made in insect cells after storage in various formulation media

Authors: Alisson Lynch, Ann E Meyers, Anna-Lise Williamson, Edward P Rybicki

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Background

HIV-1 Pr55gag virus-like particles (VLPs) expressed by baculovirus in insect cells are considered to be a very promising HIV-1 vaccine candidate, as they have been shown to elicit broad cellular immune responses when tested in animals, particularly when used as a boost to DNA or BCG vaccines. However, it is important for the VLPs to retain their structure for them to be fully functional and effective. The medium in which the VLPs are formulated and the temperature at which they are stored are two important factors affecting their stability.

Findings

We describe the screening of 3 different readily available formulation media (sorbitol, sucrose and trehalose) for their ability to stabilise HIV-1 Pr55gag VLPs during prolonged storage. Transmission electron microscopy (TEM) was done on VLPs stored at two different concentrations of the media at three different temperatures (4°C, –20°C and −70°C) over different time periods, and the appearance of the VLPs was compared. VLPs stored in 15% trehalose at −70°C retained their original appearance the most effectively over a period of 12 months. VLPs stored in 5% trehalose, sorbitol or sucrose were not all intact even after 1 month storage at the temperatures tested. In addition, we showed that VLPs stored under these conditions were able to be frozen and re-thawed twice before showing changes in their appearance.

Conclusions

Although the inclusion of other analytical tools are essential to validate these preliminary findings, storage in 15% trehalose at −70°C for 12 months is most effective in retaining VLP stability.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Munier CML, Andersen CR, Kelleher AD: HIV Vaccines: Progress to Date. Drugs. 2011, 71: 387-414.PubMed Munier CML, Andersen CR, Kelleher AD: HIV Vaccines: Progress to Date. Drugs. 2011, 71: 387-414.PubMed
4.
go back to reference Doan LX, Li M, Chen C, Yao Q: Virus-like particles as HIV-1 vaccines. Rev Med Virol. 2003, 15: 75-88.CrossRef Doan LX, Li M, Chen C, Yao Q: Virus-like particles as HIV-1 vaccines. Rev Med Virol. 2003, 15: 75-88.CrossRef
5.
go back to reference Yao Q, Bu Z, Vzorov A, Yang C, Compans RW: Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine. 2003, 21: 638-643. 10.1016/S0264-410X(02)00572-8.PubMedCrossRef Yao Q, Bu Z, Vzorov A, Yang C, Compans RW: Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine. 2003, 21: 638-643. 10.1016/S0264-410X(02)00572-8.PubMedCrossRef
6.
go back to reference Deml L, Speth C, Dietrich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005, 42: 259-277. 10.1016/j.molimm.2004.06.028.PubMedCrossRef Deml L, Speth C, Dietrich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005, 42: 259-277. 10.1016/j.molimm.2004.06.028.PubMedCrossRef
7.
go back to reference Vicente T, Roldao A, Peixoto C, Carrondo M, Alves PM: Large-scale production and purification of VLP-based vaccines. J Invert Pathol. 2011, 107: 42-48.CrossRef Vicente T, Roldao A, Peixoto C, Carrondo M, Alves PM: Large-scale production and purification of VLP-based vaccines. J Invert Pathol. 2011, 107: 42-48.CrossRef
8.
go back to reference Wagner R, Fliessbach H, Wanner G, Motz G, Niedrig M, Deby G, von Brunn A, Wolf H: Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol. 1992, 127: 117-137. 10.1007/BF01309579.PubMedCrossRef Wagner R, Fliessbach H, Wanner G, Motz G, Niedrig M, Deby G, von Brunn A, Wolf H: Studies on processing, particle formation and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol. 1992, 127: 117-137. 10.1007/BF01309579.PubMedCrossRef
9.
go back to reference Jaffray A, Shephard E, van HJ, Williamson C, Williamson AL, Rybicki EP: Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol. 2004, 85: 409-413. 10.1099/vir.0.19396-0.PubMedCrossRef Jaffray A, Shephard E, van HJ, Williamson C, Williamson AL, Rybicki EP: Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol. 2004, 85: 409-413. 10.1099/vir.0.19396-0.PubMedCrossRef
10.
go back to reference Chege GK, Shephard E, Meyers AE, van Harmelen JH, Williamson C, Lynch A, Gray CM, Rybicki EP, Williamson AL: HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol. 2008, 89: 2214-2227. 10.1099/vir.0.83501-0.PubMedCrossRef Chege GK, Shephard E, Meyers AE, van Harmelen JH, Williamson C, Lynch A, Gray CM, Rybicki EP, Williamson AL: HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol. 2008, 89: 2214-2227. 10.1099/vir.0.83501-0.PubMedCrossRef
11.
go back to reference Chege GK, Thomas R, Shephard E, Meyers AE, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL: A prime-boost immunization regimen using recombinant BCG and Pr55gag virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine. 2009, 27: 4857-4866. 10.1016/j.vaccine.2009.05.064.PubMedCrossRef Chege GK, Thomas R, Shephard E, Meyers AE, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL: A prime-boost immunization regimen using recombinant BCG and Pr55gag virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine. 2009, 27: 4857-4866. 10.1016/j.vaccine.2009.05.064.PubMedCrossRef
12.
go back to reference Ye L, Wen W, Dong K, Pan L, Bu Z, Compans RW, Zhang H, Yang C: Immunisation with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses. J Biomed Biotechnol. 2010, 10: 1-11.CrossRef Ye L, Wen W, Dong K, Pan L, Bu Z, Compans RW, Zhang H, Yang C: Immunisation with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses. J Biomed Biotechnol. 2010, 10: 1-11.CrossRef
13.
go back to reference Galazka A, Milstien A, Zaffran J: Thermostability of vaccines. World Health Programme for Vaccines and Immunization. 1998, 1-64. Galazka A, Milstien A, Zaffran J: Thermostability of vaccines. World Health Programme for Vaccines and Immunization. 1998, 1-64.
14.
go back to reference Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR: Thermal stability of vaccines. J Pharm Sci. 2003, 92: 218-231.PubMedCrossRef Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR: Thermal stability of vaccines. J Pharm Sci. 2003, 92: 218-231.PubMedCrossRef
15.
go back to reference Hochachka PN, Somero GN: Biochemical Adaptation. 2002 Hochachka PN, Somero GN: Biochemical Adaptation. 2002
16.
go back to reference Bolen DW: Effects of naturally occurring osmolytes on protein stability and solubility: issues important in protein crystallization. Methods. 2004, 34: 312-322. 10.1016/j.ymeth.2004.03.022.PubMedCrossRef Bolen DW: Effects of naturally occurring osmolytes on protein stability and solubility: issues important in protein crystallization. Methods. 2004, 34: 312-322. 10.1016/j.ymeth.2004.03.022.PubMedCrossRef
17.
go back to reference Kissman J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedivick TS, Middaugh R: Physical stabilization of Norwalk virus-like particles. J Pharm Sci. 2008, 97: 4208-4218. 10.1002/jps.21315.CrossRef Kissman J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedivick TS, Middaugh R: Physical stabilization of Norwalk virus-like particles. J Pharm Sci. 2008, 97: 4208-4218. 10.1002/jps.21315.CrossRef
18.
go back to reference Peixoto C, Sousa MF, Silva AC, Carrondo MJ, Alves PM: Downstream processing of triple layered rotavirus like particles. J Biotechnol. 2007, 127: 452-461. 10.1016/j.jbiotec.2006.08.002.PubMedCrossRef Peixoto C, Sousa MF, Silva AC, Carrondo MJ, Alves PM: Downstream processing of triple layered rotavirus like particles. J Biotechnol. 2007, 127: 452-461. 10.1016/j.jbiotec.2006.08.002.PubMedCrossRef
19.
go back to reference Amorij J-P, Meulenaar J, Hinrichs WLJ, Stegmann T, Huckriede A, Coenen F, Frijlink HW: Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine. 2007, 25: 6447-6457. 10.1016/j.vaccine.2007.06.054.PubMedCrossRef Amorij J-P, Meulenaar J, Hinrichs WLJ, Stegmann T, Huckriede A, Coenen F, Frijlink HW: Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine. 2007, 25: 6447-6457. 10.1016/j.vaccine.2007.06.054.PubMedCrossRef
20.
go back to reference Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, Hanke T, Williamson AL, Williamson C: Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol. 2006, 87: 399-410. 10.1099/vir.0.81379-0.PubMedCrossRef Burgers WA, van Harmelen JH, Shephard E, Adams C, Mgwebi T, Bourn W, Hanke T, Williamson AL, Williamson C: Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol. 2006, 87: 399-410. 10.1099/vir.0.81379-0.PubMedCrossRef
21.
go back to reference van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL, Williamson C: Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine. 2003, 21: 4380-4389. 10.1016/S0264-410X(03)00406-7.PubMedCrossRef van Harmelen JH, Shephard E, Thomas R, Hanke T, Williamson AL, Williamson C: Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine. 2003, 21: 4380-4389. 10.1016/S0264-410X(03)00406-7.PubMedCrossRef
22.
go back to reference Morikawa Y, Shibuya M, Goto T, Sano K: In vitro processing of human immunodeficiency virus type 1 Gag virus-like particles. Virology. 2000, 272: 366-374. 10.1006/viro.2000.0370.PubMedCrossRef Morikawa Y, Shibuya M, Goto T, Sano K: In vitro processing of human immunodeficiency virus type 1 Gag virus-like particles. Virology. 2000, 272: 366-374. 10.1006/viro.2000.0370.PubMedCrossRef
23.
go back to reference Bozzola JJ, Russell LD: Electron Microscopy: Principles and Techniques for Biologists. 1999 Bozzola JJ, Russell LD: Electron Microscopy: Principles and Techniques for Biologists. 1999
24.
go back to reference Grgacic EVL, Anderson DA: Virus-like particles: Passport to immune recognition. Methods. 2006, 40: 60-65. 10.1016/j.ymeth.2006.07.018.PubMedCrossRef Grgacic EVL, Anderson DA: Virus-like particles: Passport to immune recognition. Methods. 2006, 40: 60-65. 10.1016/j.ymeth.2006.07.018.PubMedCrossRef
25.
go back to reference Pease LF, Lipin DI, Tsai DH, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ: Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng. 2009, 102: 845-855. 10.1002/bit.22085.PubMedCrossRef Pease LF, Lipin DI, Tsai DH, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ: Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng. 2009, 102: 845-855. 10.1002/bit.22085.PubMedCrossRef
Metadata
Title
Stability studies of HIV-1 Pr55gagvirus-like particles made in insect cells after storage in various formulation media
Authors
Alisson Lynch
Ann E Meyers
Anna-Lise Williamson
Edward P Rybicki
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-210

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine